Browsing by Subject
Now showing items 1-6 of 6
-
Finding MYCure
(Taylor and Francis, 2019-06-20) -
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
(American Society of Clinical Oncology, 2021-06-20) -
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study
(American Society of Clinical Oncology, 2022-02-10)